120737-59-9

Usage

Uses

Used in Pharmaceutical Industry:
4-N-Boc-2-Methyl-piperazine is used as a key intermediate in the synthesis of prazosin-related compounds for their blocking activity towards α-adrenoreceptors. This application is significant in the development of medications targeting various conditions, such as hypertension and benign prostatic hyperplasia, where modulation of α-adrenoreceptor activity is crucial.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 4-N-Boc-2-Methyl-piperazine serves as a valuable building block for the design and synthesis of novel α-adrenoreceptor antagonists. Its unique chemical structure allows researchers to explore new therapeutic possibilities and develop more effective treatments for various medical conditions.
Used in Drug Development:
4-N-Boc-2-Methyl-piperazine plays a vital role in drug development, particularly in the creation of prazosin analogs with improved pharmacological properties. These analogs can potentially exhibit enhanced efficacy, selectivity, and reduced side effects, leading to better patient outcomes and improved quality of life.

InChI:InChI=1/C10H20N2O2/c1-8-7-12(6-5-11-8)9(13)14-10(2,3)4/h8,11H,5-7H2,1-4H3

Upstream product

• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 109-07-9 (RS)-2-methylpiperazine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 34619-03-9 tert-butyldicarbonate 
• 73371-96-7 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 
• 55130-19-3 di-tert-butyl dicarbonate 
• 91612-43-0 2-<<(tert-butoxycarbonyl)oxy>imino>-2-phenylacetonitrile 

Downstream Products

• 262295-73-8 tert-butyl 4-[4-cyano-3-(trifluoromethyl)phenyl]-3-methylpiperazine-1-carboxylate 
• 866538-95-6 4-(2-fluoro-4-nitro-phenyl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 1018895-60-7 tert-butyl 4-(3,4-dinitrophenyl)-3-methylpiperazine-1-carboxylate 
• 866538-99-0 4-(4-amino-2-fluoro-phenyl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-05-1 4-[2-fluoro-4-(5-hydroxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-02-8 4-(4-benzyloxycarbonylamino-2-fluoro-phenyl)-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-11-9 4-[4-(5-azidomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-14-2 4-[4-(5-aminomethyl-2-oxo-oxazolidin-3-yl)-2-fluoro-phenyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-08-4 4-[2-fluoro-4-(5-methanesulfonyloxymethyl-2-oxo-oxazolidin-3-yl)-phenyl]-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 866539-17-5 4-{4-[5-(acetylamino-methyl)-2-oxo-oxazolidin-3-yl]-2-fluoro-phenyl}-3-methyl-piperazine-1-carboxylic acid tert-butyl ester 
• 262295-74-9 (+/-)-4-(2-methylpiperazin-1-yl)-2-(trifluoromethyl)benzonitrile 
• 337530-59-3 tert-butyl 3-methyl-4-(4-nitrophenyl)piperazine-1-carboxylate 
• 845617-88-1 rac-3-Methyl-4-(4-trifluoromethyl-phenyl)-piperazine-1-carboxylic acid tert-butyl ester 
• 841281-94-5 2-chloro-4-cyclohexylamino-6-(4-tert-butoxycarbonyl-2-methylpiperazin-1-yl)-1,3,5-triazine 

Relevant academic research and scientific papers

Structure-Activity Relationships in Prazosin-Related Compounds. 2. Role of the Piperazine Ring on α-Blocking Activity

Several prazosin-related compounds have been synthesized and evaluated for their blocking activity toward α-adrenoreceptors.The structural modification performed on the prazosin structure included the replacement of the piperazine ring with 2,3-dialkylpiperazine or 1,2-cyclohexanediamine moieties to characterize a lipophilic binding pocket in the α1 adrenoreceptor surface.Cyclohexanediamine derivatives 3-6 were almost devoid of potency and selectivity, whereas dialkylpiperazine compounds 7-14 showed high affinity and selectivity toward α1-adrenoreceptors.The cis derivative 13 (cyclazosin) was the most potent and selective with an α1/α2 selectivity ratio value of 7800.The particular trend of antagonist activity within cis/trans stereoisomeric compounds not only supports the presence of a lipophilic binding area on α1-adrenoreceptor surface but also suggests that the lipophilic pocket is endowed with a well-defined size and spatial orientation.The most active compound of the series, 13, was tested also in vivo for antihypertensive activity on spontaneously hypertensive rats.It showed an interesting long-lasting hypotensive effect, very similar to that of doxazosin, which was statistically significant 12 h after oral administration.

Optimization of piperazine-derived ureas privileged structures for effective –antiadenovirus agents

In recent years, human adenovirus (HAdV) infections have shown a high clinical impact in both immunosuppressed and immunocompetent patients. The research into specific antiviral drugs for the treatment of HAdV infections in immunocompromised patients cons

New 4-Acyl-1-phenylaminocarbonyl-2-phenylpiperazine Derivatives as Potential Inhibitors of Adenovirus Infection. Synthesis, Biological Evaluation, and Structure-activity Relationships

The search for human adenovirus (HAdV)-specific antiviral drugs for the treatment of HAdV infections in immunocompromised patients continues to be a challenging goal for medicinal chemistry. Here, we report the synthesis, biological evaluation, and struct

PARP inhibitor containing phthalazine-1 -(2H)-ketone structure as well as preparation method and medical application of PARP inhibitor

The invention discloses a PARP inhibitor containing a phthalazine-1(2H)-ketone structure as well as a preparation method and medical application of the PARP inhibitor. A compound as shown in a generalformula (I) or a pharmaceutically acceptable salt there

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.

PIPERAZINE DERIVATIVES AS ANTIVIRAL AGENTS WITH INCREASED THERAPEUTIC ACTIVITY

The present invention provides 2-phenylpiperazine derivatives having a benzofuran-2-yl group which contributes to increase the antiviral activity as well as, for some substituents, the CC50, giving more active and less cytotoxic compounds. Alth

INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING

The present application is directed to compounds of Formula I: compounds comprising these compounds and their uses, for example as medicaments for the treatment of diseases, disorders or conditions mediated or treatable by inhibition of binding between WDR5 protein and its binding partners.

HEPATITIS B VIRAL ASSEMBLY EFFECTORS

Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.

Design, synthesis and antibacterial evaluation of novel fluoroquinolone and its derivatives

Gatifloxacin isomers, [1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(2- methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid] and a series of its derivatives were designed and synthesized and evaluated for their in vitro antibacterial activities. Pre

Hetero-difunctional dimers as building blocks for the synthesis of poly(amidoamine)s with hetero-difunctional chain terminals and their derivatives

This article reports on a simple and straightforward preparation method of poly(amidoamine)s (PAAs) with hetero-difunctional chain ends as well as of several up to now hardly obtainable PAA derivatives of biotechnological interest, such as for instance PAAs of controlled molecular weight and narrow polydispersity mono-functionalized at one end with an acrylamide group, PAAs with star-like molecular architecture, graft-PAA-protein conjugates, "tadpole-like" PAA conjugates with hydrophobic moieties able to self assemble into nanoparticles in aqueous media. The key step was to design suitable building blocks consisting of hetero-difunctional dimers (HDDs). In particular, the HDDs considered were the mono-addition products of bis-sec-amines and bisacrylamides expected to give PAAs of proven biomedical potential and were obtained as hydrochlorides or trifluoroacetates. In this form, they could be indefinitely kept dormant at 0-5 °C in the dry state, whereas at room temperature and in aqueous media, they polymerized at pH > 7.5. The preparation of the above-cited PAA derivatives did not necessarily involve the preliminary synthesis of hetero-difunctional PAAs but was directly achieved by one-pot polymerization of HDDs in the presence of the substrates of interest.